Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

By sjmartinez • May 19, 2025

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Epub ahead of print. PMID: 40384092.

Tags: Anti-CTLA-4, anti-PD-L1, Cedars Sinai DoM, Hematology/Oncology, immune checkpoint inhibitors, Publications, safety, survival

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program

Wang N, DiCorpo DA, Zhang Y, Kleinbrink E, Arnett DK, Barnard J, Blangero J, Bowden DW, Carson AP, Chen YI, Chung MK, Curran JE, Darbar[...]

Defining Diagnostic Excellence and Missed Diagnostic Opportunity for the Emergency Department Setting

Berdahl CT, Schiff GD, Venkatesh AK, Seferian EG, Torbati SS, Ptacek MP, Carrascoza-Bolanos J, Qureshi N, Nuckols TK; Multidisciplinary ED Diagnostic Excellence Panel. Defining Diagnostic[...]

The Family Perspectives Project: development and preliminary feasibility of a chaplain-delivered emotional support intervention for families of critically ill patients

Modes ME, Kross EK, Duru OK, Sherman A, Ahluwalia SC, Walling AM, Lazor P, Nuckols TK. The Family Perspectives Project: development and preliminary feasibility of[...]